TABLE 3

ZINC Compounds identified by virtual screening and tested for activity

	I_PYD/I_Control Mean ± S.E.M. %			EC₅₀μM (%)^a			I_PYD/I_Control Mean ± S.E.M. %			EC₅₀μM (%)^aμM (%)^a
	GluN2A	GluN2B	GluN2C	GluN2D	GluN2C		GluN2A	GluN2B	GluN2C	GluN2D	GluN2C
181^c	100 ± 1.5	96 ± 0.61	114 ± 2.3	99 ± 1.1	N.D. (130)	187^b	97 ± 1.8	95 ± 2.6	97 ± 1.4	94 ± 0.82	N.D.
182^c	96 ± 1.3	96 ± 0.93	108 ± 2.4	97 ± 0.70	N.D. (114)	188^b	95 ± 1.7	92 ± 1.9	89 ± 1.2	89 ± 0.86	N.D.
183^c	99 ± 4.2	96 ± 2.1	120 ± 2.2	83 ± 0.84	N.D. (115)	189^b	97 ± 0.56	94 ± 1.5	93 ± 0.45	91 ± 0.90	N.D.
184^c	92 ± 3.9	91 ± 1.9	134 ± 4.1	103 ± 6.1	9 (132)	190^d	96 ± 6.2	65 ± 1.0	71 ± 0.27	67 ± 0.78	N.D.
185^d	97 ± 1.5	90 ± 1.5	93 ± 0.96	76 ± 2.2	N.D.	191^b	94 ± 1.6	94 ± 4.2	90 ± 1.4	90 ± 0.41	N.D.
186^d	76 ± 5.2	55 ± 4.5	48 ± 2.5	36 ± 1.9	N.D.	192^c	100 ± 6.9	90 ± 0.99	85 ± 0.37	84 ± 0.52	N.D.

All compounds were coapplied with 100 glutamate and 30 μM glycine. The concentration-effect curve was recorded for active compounds and fitted by the Hill equation (see Materials and Methods) to determine the EC₅₀ value; parentheses show the response to 100 μM test compound as a percentage of the response to maximally effective concentrations of glutamate (100 μM) and glycine (30 μM) for compounds tested at multiple concentrations. Compounds were screened at ^b10 μM, ^c30 μM, and ^d100 μM depending on availability and solubility. N.D., not determined. For all compounds, data are from three to 12 oocytes from one to three different frogs.